{"id":2770,"date":"2026-08-24T18:05:09","date_gmt":"2026-08-24T18:05:09","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/en\/?post_type=product&p=2770"},"modified":"2026-08-24T18:07:45","modified_gmt":"2026-08-24T18:07:45","slug":"buy-ace-031-1mg-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/en\/product\/buy-ace-031-1mg-in-switzerland\/","title":{"rendered":"ACE-031 (1MG)"},"content":{"rendered":"

What Is ACE-031 and Why Buy It for Research?<\/strong><\/h2>\n

Buy ACE-031 1mg in Switzerland for research into myostatin inhibition, muscle regulation, and TGF-\u03b2 superfamily signaling. Specifically, ACE-031 (also known as Ramatercept) is a recombinant fusion protein engineered from the extracellular ligand-binding domain of human activin receptor type IIB (ActRIIB) linked to the Fc region of human immunoglobulin G1 (IgG1). Structurally, this fusion protein creates a soluble ActRIIB-Fc construct that functions as a decoy receptor for select TGF-\u03b2 family ligands.<\/p>\n

In scientific research, ACE-031 serves as a molecular tool for studying ligand-receptor interactions within the transforming growth factor-beta (TGF-\u03b2) superfamily. Researchers consider this fusion protein particularly valuable for investigating myostatin (GDF-8) signaling pathways and their role in skeletal muscle regulation. Furthermore, ACE-031 is supplied as a lyophilized powder in a 1mg format for laboratory use. Therefore, researchers seeking to source this fusion protein for their work will find it readily available through trusted suppliers.<\/p>\n

ACE-031 Research Overview: Buy ACE-031 1mg in Switzerland for Myostatin Studies<\/strong><\/h2>\n

Centrally, research into ACE-031 has focused on its function as a soluble ligand trap for myostatin and related negative regulators of muscle mass. Endogenously, myostatin (GDF-8) acts as a potent inhibitor of skeletal muscle growth by binding to ActRIIB receptors on muscle cells. ACE-031 disrupts this inhibitory signal by binding to myostatin and other ActRIIB ligands, including GDF11 and activins, before they can interact with endogenous cell-surface receptors.<\/p>\n

Notably, research has demonstrated that ACE-031 promotes muscle growth by removing the biological “brakes” on myogenic development. Investigators have studied this fusion protein in various research contexts, including preclinical models of muscle wasting, cachexia, and neuromuscular disorders. Accordingly, researchers can buy ACE-031 1mg in Switzerland from Core Peptides to support their investigations into myostatin inhibition and muscle regulation pathways.<\/p>\n

How Does ACE-031 Work in Research?<\/strong><\/h2>\n

Mechanistically, ACE-031’s proposed action involves functioning as a soluble decoy receptor that sequesters TGF-\u03b2 superfamily ligands. The ActRIIB extracellular domain within ACE-031 adopts a characteristic cysteine knot fold stabilized by disulfide bonds, creating a ligand-binding surface that accommodates mature TGF-\u03b2 superfamily members. Consequently, when ACE-031 binds to myostatin, activins, and related ligands, it prevents these molecules from activating endogenous ActRIIB receptors on cell surfaces.<\/p>\n

The Fc domain of ACE-031 serves multiple pharmaceutical purposes in this construct. Specifically, the human IgG1 Fc region naturally dimerizes, creating a bivalent molecule with two ActRIIB binding domains that increase ligand-binding avidity. Additionally, binding to the neonatal Fc receptor (FcRn) protects the protein from lysosomal degradation through a pH-dependent recycling mechanism, extending the circulating half-life to approximately 10 to 15 days. Thus, ACE-031 demonstrates a linear pharmacokinetic profile with sustained ligand sequestration capability.<\/p>\n

Furthermore, the inclusion of the Fc domain facilitates purification using Protein A affinity chromatography during manufacturing and may retain partial Fc effector functions. A short peptide linker connects the ActRIIB extracellular domain to the IgG1 Fc domain, providing flexibility for independent domain movement and spatial separation between the ligand-binding and Fc domains.<\/p>\n

Why Is ACE-031 Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study ACE-031 because it represents a well-characterized ActRIIB-Fc fusion protein that enables investigation of myostatin and activin signaling pathways. In fact, this fusion protein offers a focused tool for studying ligand sequestration mechanisms and downstream signaling modulation within the TGF-\u03b2 superfamily.<\/p>\n

Preclinical studies have demonstrated that ACE-031 increases skeletal muscle mass and strength in normal mice and in murine models of muscular dystrophy. For example, research in the common marmoset showed that ACE-031 administration produced significant increases in body weight and lean body mass from baseline. Ultimately, researchers can buy ACE-031 1mg in Switzerland to access a research tool that may help uncover mechanisms underlying muscle regulation, tissue regeneration, and muscle-wasting pathways.<\/p>\n

ACE-031 Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nEvidence Level<\/th>\n<\/tr>\n<\/thead>\n
Myostatin Inhibition<\/td>\nLigand sequestration, ActRIIB signaling blockade<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n
Skeletal Muscle Growth<\/td>\nMuscle hypertrophy, fiber cross-sectional area<\/td>\nAnimal \/ Preclinical<\/td>\n<\/tr>\n
Muscle Wasting Disorders<\/td>\nCachexia, age-related muscle loss, metabolic diseases<\/td>\nAnimal \/ Preclinical<\/td>\n<\/tr>\n
Neuromuscular Diseases<\/td>\nDuchenne muscular dystrophy (DMD), ALS models<\/td>\nAnimal \/ Preclinical<\/td>\n<\/tr>\n
TGF-\u03b2 Superfamily Signaling<\/td>\nLigand-receptor interactions, pathway modulation<\/td>\nMechanistic \/ In Vitro<\/td>\n<\/tr>\n
Bone and Fat Metabolism<\/td>\nBone mineral density, adiponectin modulation<\/td>\nEmerging Research<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

ACE-031 Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
ACE-031<\/td>\nMyostatin inhibition, muscle growth<\/td>\nActRIIB-Fc decoy receptor (ligand trap)<\/td>\nBinds myostatin, activins, GDF11; long half-life<\/td>\n<\/tr>\n
Follistatin<\/td>\nMyostatin inhibition<\/td>\nNatural binding protein<\/td>\nEndogenous inhibitor; does not strongly bind BMP9\/10<\/td>\n<\/tr>\n
Bimagrumab<\/td>\nMyostatin inhibition<\/td>\nAnti-ActRII monoclonal antibody<\/td>\nCompetitively binds ActRII with greater affinity<\/td>\n<\/tr>\n
ACE-083<\/td>\nMuscular dystrophy<\/td>\nModified ligand trap<\/td>\nDoes not bind BMP9\/10; improved safety profile<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, ACE-031 differs from other myostatin inhibitors in its mechanism and ligand-binding profile. On the one hand, ACE-031 acts as a soluble receptor decoy that traps multiple TGF-\u03b2 ligands, including myostatin, activins, and GDF11. On the other hand, follistatin is a natural binding protein that antagonizes myostatin through direct protein interaction. In contrast, ACE-031’s broader ligand-binding spectrum may offer more comprehensive pathway inhibition but has also been associated with safety considerations related to BMP inhibition.<\/p>\n

Research Applications for ACE-031 in Switzerland<\/strong><\/h2>\n

Scientists have investigated ACE-031 across several research domains:<\/p>\n